News and Insights

The latest news and insights from Genoa Healthcare.

  • Clinical Insights

Currently available and emerging therapy options for treatment-resistant depression

Studies show that 50% of people with major depressive disorder don’t respond adequately to initial antidepressant treatment.1 Additionally, an estimated 30% of people with major depressive disorder (MDD) experience treatment-resistant...

  • Aug 2nd, 2023
  • Clinical Insights

Frequently asked questions: naloxone (Narcan®)

Narcan® information and sources were taken from www.narcan.com. 1. FDA Approves First Over-the-Counter Naloxone Nasal Spray. 3/29/2023. FDA Approves First Over-the-Counter Naloxone Nasal Spray | FDA

  • Mar 29th, 2023
  • Clinical Insights

Frequently asked questions: buprenorphine-containing products

Information and sources on buprenorphine-containing products were taken from www.sublocade.com and www.suboxone.com.

  • Mar 6th, 2023
  • Clinical Insights

What’s on the horizon: four emerging trends in the medication-assisted treatment space

1X-Waiver no longer need to treat opioid use disorder. (2023, January 13). ACEP. 2. Sublocade. 3.BMC launces app to help providers treat patients with opioid use disorder. (2021, March 22)....

  • Mar 6th, 2023
  • Clinical Insights

Why medication-assisted treatment is essential for improving patient outcomes

1. Methadone and buprenorphine reduce risk of death after opioid overdose. (2018, June 19). NIH. 2. Methadone and buprenorphine reduce risk of death after opioid overdose. (2018, June 19). NIH....

  • Mar 6th, 2023
  • Clinical Insights

Fact or fiction: 6 things to know about medication-assisted treatment

1.Advancing pharmacological treatments for opioid use disorder (ADaPT-OUD). (2018, December 18). NIH. 2. Medications for substance use disorders (2023, February 21). SAMHSA. 3. Medications for substance use disorders (2023, February...

  • Mar 1st, 2023